Insufficient evidence / under studyCgradePlausibility · PlausibleNeuromodulation
Low-intensity focused ultrasound can noninvasively reach deep and superficial brain targets with millimeter-scale spatial precision and reversibly modulate neural excitability, with reported effects that may be excitatory or inhibitory depending on the acoustic parameters used. Human evidence is early and parameter-sensitive: a systematic review of interventional human studies found both excitatory and inhibitory effects in motor and sensory regions while noting heterogeneity and incompletely understood mechanisms (Ho 2025), and early device and clinical work demonstrates feasible, well-tolerated targeting and preliminary cognitive signals (Bawiec 2025; JAMA Netw Open 2025). This is neuromodulation, not diagnostic ultrasound imaging — it should not be confused with full-body ultrasound scanning systems, which image anatomy and make no neuromodulatory claim.
Origin & lineage
Low-intensity focused ultrasound (LIFU), also termed transcranial focused ultrasound (tFUS), descends from work showing that focused acoustic energy delivered through the skull at non-ablative intensities can reversibly modulate activity in targeted neural circuits rather than destroy tissue.
Claimed mechanism
Focused acoustic pressure waves are proposed to act on neurons largely through acoustic radiation force and mechanosensitive ion channels, transiently shifting membrane excitability in the targeted volume. The effective 'dose' is defined by a parameter set — acoustic intensity, fundamental frequency, pulse-repetition/duty cycle, sonication duration, and anatomical target — and the direction of effect (facilitation vs suppression) appears to depend on this set rather than on a single fixed protocol.
Plausibility
Plausible–weak, early/under study — a mechanically grounded mechanism with preliminary human signals but parameter-dependent, bimodal, and not yet established at scale.
Evidence — grade C
Graded C because the mechanism is biophysically plausible and supported by small interventional human studies and at least one systematic review, yet the literature is heterogeneous, strongly parameter-dependent (effects can be excitatory or inhibitory), and lacks large confirmatory randomized trials for defined clinical indications. The evidence supports feasibility and probable neuromodulatory effect more than it supports any specific therapeutic claim.
Cross-reference
Within Neuromodulation its sibling is GENUS (40 Hz sensory gamma stimulation); LIFU/tFUS is distinct from full-body ultrasound imaging systems (diagnostic, not neuromodulatory) and from high-intensity focused ultrasound, which is ablative rather than reversible neuromodulation.
Market
Makers: Class examples are research- and clinical-grade focused-ultrasound neuromodulation system developers (e.g., wearable/steerable transcranial LIFU systems of the type described by Bawiec 2025, and transcranial pulse-stimulation platforms used in the JAMA Netw Open 2025 Alzheimer trial); listed as a device class, not an endorsement of any brand. Models: Wearable/steerable transcranial LIFU prototypes and bench/clinical tFUS and transcranial pulse-stimulation research systems. Not specified in source as standardized consumer models. Price: Not specified in source; primarily research/clinical instrumentation rather than retail consumer pricing.
Kernel — keep vs set aside
Keep — real substrate
Keep the real, dosed phenomenon under active trial: focused acoustic energy at non-ablative intensities can reach defined brain targets and reversibly modulate neural excitability in a parameter-dependent way.
Set aside — claim
Set aside consumer- or clinic-level claims of broad, reliable treatment for cognition, mood, or pain that run ahead of controlled evidence; current human data establish feasibility and probable effect, not validated clinical outcomes.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
For low-intensity neuromodulation, LIFU/tFUS is generally investigational in the United States and used under research/IDE pathways; this is distinct from high-intensity MR-guided focused ultrasound, which is FDA-cleared for ablative indications such as essential tremor and tremor-dominant Parkinson disease. Not specified in source for device-specific clearances.
EU — MDR
Not specified in source; low-intensity focused ultrasound neuromodulation systems are generally used investigationally in the EU, separate from CE-marked high-intensity ablative focused-ultrasound devices.
The anchors establish a wearable steerable transcranial LIFU system with safe, well-tolerated targeting in 20 healthy volunteers (Bawiec 2025, J Ultrasound Med), a randomized clinical trial reporting preliminary cognitive improvement with ultrasound-based transcranial pulse stimulation in Alzheimer disease (JAMA Netw Open 2025, e2459170), and a systematic review of human tFUS finding both excitatory and inhibitory motor/sensory effects with incompletely understood mechanisms (Ho 2025, J NeuroEng Rehabil). Together they support an early, feasibility-to-preliminary-efficacy evidence level consistent with grade C.